FDA approves new drug for hypoparathyroidism, a rare disorder
The FDA has approved Yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism. Yorvipath was not studied in adults with acute post-surgical …
Palopegteriparatide (YORVIPATH) in Hypoparathyroidism National Drug Mini-monograph June 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The …
YORVIPATH: First Hypoparathyroidism Treatment in Adults
Aug 16, 2024 · YORVIPATH is a prodrug of parathyroid hormone (PTH 1-34) administered once daily, designed to provide parathyroid hormone levels within the normal physiological range …
FDA approves hypoparathyroidism treatment Yorvipath
Aug 14, 2024 · Hypoparathyroidism is considered chronic if it persists for longer than six months. Yorvipath contains palopegteriparatide, a prodrug that is modified in the body over time into …
Your Guide to Yorvipath for Hypoparathyroidism - WebMD
Feb 13, 2025 · Is Yorvipath Right for Me? Your health care provider may consider treatment with Yorvipath if you have hypoparathyroidism and have been taking calcium and vitamin D …
Chronic Hypoparathyroidism—Current and Emerging Therapies
Nov 1, 2025 · Conventional treatment for hypoparathyroidism with calcium salts and activated vitamin D has limitations such as inadequate control of symptomatic hypocalcemia and large …
Yorvipath for Hypoparathyroidism - HealthCentral
Jan 29, 2025 · What Does Research Show About Yorvipath for Hypoparathyroidism? The FDA approved Yorvipath based on evidence from a clinical trial involving 82 adults with chronic …
Yorvipath Approved for Treatment of Hypoparathyroidism
Aug 16, 2024 · The Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in …
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism …
Oct 8, 2024 · TransCon PTH (palopegteriparatide, approved under the brand name YORVIPATH in the European Union and certain other countries as a replacement therapy indicated for the …
PTH Replacement Therapies: Current Options and What’s Ahead
Jul 3, 2025 · The table below summarizes the three key therapies—Natpara, Forteo, and YORVIPATH—with attention to their origin, approval status, and role in clinical practice. …